Immunohistochemical expression of BRCA2 protein and allelic loss at the BRCA2 locus in prostate cancer

International Journal of Cancer

Volumn 78, Issue 1, 1998, Pages 1-7

  Edwards, Stephen M ^a   Dunsmuir, William D ^a,c,d   Gillett, Cheryl E ^d   Lakhani, Sunil R ^b   Corbishley, Catherine ^c   Young, Martin ^c   Kirby, Roger S ^c   Dearnaley, David P ^a,e   Dowe, Anna ^e   Ardern Jones, Audrey ^e   Kelly, J O ^a   Spurr, Nigel ^f   Barnes, Diana M ^d   Eeles, Rosalind A ^a,e  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c ST GEORGE S HOSPITAL   (United Kingdom)

^d GUY S HOSPITAL   (United Kingdom)

^e INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^f GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA2 PROTEIN; DNA;

ALLELE; ARTICLE; CONTROLLED STUDY; FAMILIAL CANCER; GENE LOCUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN LOCALIZATION; TUMOR SUPPRESSOR GENE;

BRCA2 PROTEIN; GENE DELETION; GENETIC MARKERS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASM PROTEINS; POLYMERASE CHAIN REACTION; PROSTATE; PROSTATIC NEOPLASMS; TRANSCRIPTION FACTORS;

EID: 0031821621     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980925)78:1<1::AID-IJC1>3.0.CO;2-U     Document Type: Article

References (28)

1. ANDERSON, D.E. and BADZIOCH, M.D., Familial breast-cancer risks. Effects of prostate and other cancers. Cancer, 72, 114-119 (1993).
2. BANERJEE, A., Xu, HJ., Hu, S.X., ARAUJO, D., TAKAHASHI, R., STANBRIDGE, E.J. and BENEDICT, W.F., Changes in growth and tumorigenicity following reconstitution of retinoblastoma-gene function in various human cancer cell types by microcell transfer of chromosome 13. Cancer Res., 52, 6297-6304 (1992).
3. BECKMANN, M.W., PICARD, F., AN, H.X., VAN ROEYEN, C.R., DOMINIK, S.I., MOSNY, D.S., SCHNURCH, H.G., BENDER, H.G. and NIEDERACHER, D., Clinical impact of detection of loss of heterozygosity of BRCA1 and BRCA2 markers in sporadic breast cancer. Brit. J. Cancer, 73, 1220-1226 (1996).
4. CARTER, B.S., EWING, C.M., WARD, W.S., TREIGER, B.F., AALDERS, T.W., SCHALKEN, J.A., EPSTEIN, J.I. and ISAACS, W.B., Allelic loss of chromosomes 16q and l0q in human prostate cancer. Proc. natl. Acad. Sci. (Wash.), 87, 8751-8755 (1990).
5. CHER, M.L., MACGROGAN, D., BOOKSTEIN, R., BROWN, J.A., JENKINS, R.B. and JENSEN, R.H., Comparative genomic hybridization, allelic imbalance, and fluorescence in situ hybridization on chromosome 8 in prostate cancer. Genes Chromosomes Cancer, 11, 153-162 (1994).
6. CLETON-JANSEN, A.M., COLLINS, N., LAKHANI S.R., WEISSENBACH, J., DEVILEE, P., CORNELISSE, C.J. and STRATTON, M.R., Loss of heterozygosity in sporadic breast tumours at the BRCA2 locus on chromosome 13q12-q13. Brit. J. Cancer, 72, 1241-1244 (1995).
7. COLLINS, N., MCMANUS, R., WOOSTER, R., MANGION, J., SEAL, S., LAKHANI, S.R., ORMISTON, W., DALY, P.A., FORD, D., EASTON, D.F. and STRATTON, M.R., Consistent loss of the wild-type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q2-13. Oncogene, 10, 1673-1675 (1995).
8. COONEY, K.A., WETZEL, J.C., MERAJVER, S.D., MACOSKA, J.A., SINGLETON, T.P. and WOJNO, K.J., Distinct regions of allelic loss on 13q in prostate cancer. Cancer Res., 56, 1142-1145 (1996).
9. DUNSMUIR, W.D., HROUDA, D., EDWARDS, S., EELES, R. and KIRBY, R.S., Prostate cancer and the contribution of the breast-cancer-susceptibility gene (BRCA2). [Abstract] Brit. J. Urol., 79, Suppl. 4, 6 (1997).
10. EELES, R.A. and 15 OTHERS, The contribution of candidate genes to prostate-cancer susceptibility. [Abstract] In: Future Perspectives in Prostatic Disease, British Prostate Group Proceedings (1996).
11. GOLDGAR, D.E., EASTON, D.F., CANNON-ALBRIGHT, L.A. and SKOLNICK, M.H., Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J. nat. Cancer Inst., 86, 1600-1608 (1994).
12. GUDMUNDSSON, J., JOHANNESDOTTIR, G., BERGTHORSSON, J.T., ARASON, A., INGVARSSON, S., EGILSSON, V. and BARKARDOTTIR, R.B., Different tumor types from BRCA2 carriers show wild-type chromosome deletions on 13q12-q13. Cancer Res., 55, 4830-4832 (1995).
13. HALL, P.A., MCKEE, P.H., MENAGE, H.D., DOVER, R. and LANE, D.P., High levels of p53 protein in UV-irradiated normal human skin. Oncogene, 8, 203-207 (1993).
14. KIM, T.M., BENEDICT, W.F., XU, H.J., HU, S.X., GOSEWEHR, J., VELICESCU, M., YIN, E., ZHENG, J., D'ABLAING, G. and DUBEAU, L., Loss of heterozygosity on chromosome 13 is common only in the biologically more aggressive sub-types of ovarian epithelial tumors and is associated with normal retinoblastoma-gene expression. Cancer Res., 54, 605-609 (1994).
15. KUNIMI, K., BERGERHEIM, U.S., LARSSON, I.L., EKMAN, P. and COLLINS, V.P., Allelotyping of human prostatic adenocarcinoma. Genomics, 11, 530-536 (1991).
16. LAKHANI, S.R., COLLINS, N., STRATTON, M.R. and SLOANE, J.P., Atypical ductal hyperplasia of the breast: clonal proliferation with loss of heterozygosity on chromosomes 16q and 17p. J. clin. Pathol., 48, 611-615 (1995).
17. LANCASTER, J.M. and 19 OTHERS, BRCA2 mutations in primary breast and ovarian cancers. Nature Genet., 13, 238-240 (1996).
18. LATIL, A., CUSSENOT, O., FOURNIER, G. and LIDEREAU, R., The BRCA2 gene is not relevant to sporadic prostate tumours [letter]. Int. J. Cancer, 66, 282-283 (1996).
19. MIKI, Y., KATAGIRI, T., KASUMI, F., YOSHIMOTO, T. and NAKAMURA, Y., Mutation analysis in the BRCA2 gene in primary breast cancers. Nature Genet., 13, 245-247 (1996).
20. SELLERS, T.A., POTTER, J.D., RICH, S.S., DRINKARD, C.R., BOSTICK, R.M., KUSHI, L.H., ZHENG, W. and FOLSOM, A.R., Familial clustering of breast and prostate cancers and risk of post-menopausal breast cancer. J. nat. Cancer Inst., 86, 1860-1865 (1994).
21. SIGURDSSON, S., THORLACIUS, S., TOMASSON, J., TRYGGVADOTTIR, L., BENEDIKTSDOTTIR, K., FYTJORD, J.L. and JONSSON, E., BRCA2 mutation in Icelandic prostate-cancer patients. J. mol. Med., 75, 758-761 (1997).
22. STRATTON, M.R., Recent advances in understanding of genetic susceptibility to breast cancer. Hum. mol. Genet., 5, 1515-1519 (1996).
23. TENG, D.H. and 17 OTHERS, Low incidence of BRCA2 mutations in breast carcinoma and other cancers. Nature Genet., 13, 241-244 (1996).
24. THIESSEN, E.U., Concerning a familial association between breast cancer and both prostatic and uterine malignancies. Cancer, 34, 1102 (1974).
25. THORLACIUS, S., OLAFSDOTTIR, G., TRYGGVADOTTIR, L., NEUHAUSEN, S., JONASSON, J.G., TAVTIGIAN, S.V., TULINIUS, H., OGMUNDSDOTTIR, H.M. and EYFJORD, J.E., A single BRCA2 mutation in male and female breast-cancer families from Iceland with varied cancer phenotypes. Nature Genet., 13, 117-119 (1996).
26. TULINIUS, H., EGILSSON, V., OLAFSDOTTIR, G.H. and SIGVALDASON, H., Risk of prostate, ovarian, and endometrial cancer among relatives of women with breast cancer. Brit. med. J., 305, 855-857 (1992).
27. VISAKORPI, T., KALLIONIEMI, A.H., SYVANEN, A.C., HYYTINEN, E.R., KARHU, R., TAMMELA, T., ISOLA, J.J. and KALLIONIEMI, O.P., Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res., 55, 342-347 (1995).
28. WOOSTER, R. and 40 OTHERS, Identification of the breast-cancer-susceptibility gene BRCA2. Nature (Lond.), 378, 789-792 (1995).